Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pfenex

12.75
+0.0000
Volume:- -
Turnover:- -
Market Cap:437.28M
PE:-70.90
High:12.75
Open:12.75
Low:12.75
Close:12.75
Loading ...

Company Profile

Company Name:
Pfenex
Exchange:
AMEX
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX-2 (PF754). In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.